Loss of cystathionine-β-synthase contributes to elevated OXPHOS, a vulnerability in Ara-C-resistant Myeloid Leukemia in Down syndrome.
Saved in:
| Title: | Loss of cystathionine-β-synthase contributes to elevated OXPHOS, a vulnerability in Ara-C-resistant Myeloid Leukemia in Down syndrome. |
|---|---|
| Authors: | Thibodeau J; Cancer Biology Graduate Program, Wayne State University School of Medicine, Detroit, MI, USA., Zhao J; Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA., Edwards H; Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA., Polin L; Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA., Kushner J; Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA., Dzinic SH; Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA., White K; Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA., Hershberger K; Cancer Biology Graduate Program, Wayne State University School of Medicine, Detroit, MI, USA; MD/PhD Program, Wayne State University School of Medicine, Detroit, MI, USA., Su Y; Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA., Arroum T; Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI, USA., Pham L; Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI, USA., Pavelich L; Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI, USA., Awdish R; Wayne State University School of Medicine, Detroit, MI, USA., LaValley J; Wayne State University School of Medicine, Detroit, MI, USA., Boucher AC; Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA., Chen W; Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA., Li J; Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA., Bao X; Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA., Hüttemann M; Cancer Biology Graduate Program, Wayne State University School of Medicine, Detroit, MI, USA; Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI, USA., Back JB; Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA; Tumor Biology and Microenvironment Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA., Allen JE; Chimerix (a Jazz Pharmaceuticals Company), Durham, NC, USA., Prabhu VV; Chimerix (a Jazz Pharmaceuticals Company), Durham, NC, USA., Crispino JD; Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA., Taub JW; Cancer Biology Graduate Program, Wayne State University School of Medicine, Detroit, MI, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA; Division of Pediatric Hematology/Oncology, Children's Hospital of Michigan, Detroit, MI, USA; Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI, USA; Department of Pediatrics, Central Michigan University College of Medicine, Mt. Pleasant, MI, USA. Electronic address: jtaub@med.wayne.edu., Ge Y; Cancer Biology Graduate Program, Wayne State University School of Medicine, Detroit, MI, USA; Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA. Electronic address: gey@karmanos.org. |
| Source: | Biochemical pharmacology [Biochem Pharmacol] 2026 May; Vol. 247, pp. 117815. Date of Electronic Publication: 2026 Feb 13. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Science Country of Publication: England NLM ID: 0101032 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2968 (Electronic) Linking ISSN: 00062952 NLM ISO Abbreviation: Biochem Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
